Document:

Support Agreement

 Exhibit 10.1 
 SUPPORT AGREEMENT 
 This Support Agreement (this “Agreement”) is dated as of
March 31, 2009, among Fidelity National Information Services, Inc., a Georgia corporation (“Parent”), Cars Holdings, LLC, a Delaware limited liability company and a wholly owned Subsidiary of Parent (“Merger
Sub”), WPM, L.P., a Delaware limited partnership (the “Shareholder”), and solely for the purpose of Sections 4.4, 6.16 and 6.17, Metavante Technologies, Inc., a Wisconsin corporation (the “Company”).

 RECITALS 
 A.
Concurrently with the execution of this Agreement, Parent, Merger Sub and the Company have entered into an Agreement and Plan of Merger (the “Merger Agreement”), which provides, among other things and subject to Section 1.1 of
the Merger Agreement, for the Merger of the Company with and into Merger Sub, upon the terms and subject to the conditions set forth therein. 
 B. As of the date hereof and for so long as this Agreement remains in effect, the Shareholder is the record and Beneficial Owner of at least 29,784,274 shares of Company Common Stock. 
 C. As a condition to Parent’s willingness to enter into and perform its obligations under the Merger Agreement, the Shareholder has agreed to enter
into this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements contained herein, and
intending to be legally bound hereby, the parties hereby agree as follows: 
 I            CERTAIN DEFINITIONS 
 1.1. Capitalized
Terms. Capitalized terms used in this Agreement and not defined herein have the meanings ascribed to such terms in the Merger Agreement. 
 1.2. Other Definitions. For the purposes of this Agreement: 
 “Beneficial Owner” or “Beneficial
Ownership” with respect to any securities means having “beneficial ownership” of such securities (as determined pursuant to Rule 13d-3 under the Exchange Act (disregarding the reference to “within sixty days” in
Rule 13d-3(d)(1)(i))); provided, however, with respect to the Shareholder, Beneficial Ownership shall not include shares of Company Common Stock which the Shareholder has the right to receive pursuant to the Metavante Stock Purchase
Right Agreement until such shares are actually issued to the Shareholder. 
 “Company Common Stock” means common stock, par
value $0.01 per share, of the Company, and including for purposes of this Agreement all shares or other voting securities into which shares of Company Common Stock may be reclassified, sub-divided, consolidated or converted and any rights and
benefits arising therefrom (including any dividends or distributions of securities which may be declared in respect of the shares of Company Common Stock). 

 2 
  

 “Parent Shareholders Agreement” means that certain Shareholders Agreement, dated as of
the date hereof, by and among Parent and Shareholder, as the same may be amended from time to time. 
 “Parent Stock Purchase Right
Agreement” means that certain Stock Purchase Right Agreement, dated as of the date hereof, by and among Parent, Shareholder and, solely for the purpose of Sections 5.1, 5.8 and 5.10 thereof, the Company, as the same may be amended from time
to time. 
 “Representative” means, with respect to any particular Person, its officers, directors, employees, partners,
investment bankers, attorneys, accountants, agents or other advisors or representatives. 
 “Transfer” means, with respect
to a security, the sale, grant, assignment, gift-over, transfer, pledge, hypothecation, encumbrance, assignment, constructive sale, or other disposition of such security or the Beneficial Ownership thereof (including by merger (other than pursuant
to the Merger) or by operation of Law), or the entry into of any Contract to effect any of the foregoing, including, for purposes of this Agreement, the transfer or sharing of any voting power of such security. 
 II            SUPPORT OBLIGATIONS OF THE SHAREHOLDER 
 2.1. Agreement to Vote. The Shareholder irrevocably and unconditionally agrees that from and after the date hereof, at any meeting (whether annual
or special, and at each adjourned or postponed meeting) of shareholders of the Company, however called, or in connection with any written consent of the Company’s shareholders, the Shareholder will (a) appear at each such meeting or
otherwise cause all of the Owned Shares to be counted as present thereat for purposes of calculating a quorum, and respond to each request by the Company for written consent, if any, and (b) vote (or consent), or cause to be voted (or validly
execute and return and cause consent to be granted with respect to), all of the Shareholder’s shares of Company Common Stock (and all other voting securities of or equity interests in the Company and any derivative or other contractual
arrangements giving the Shareholder or any of its Affiliates (provided that for purposes of this Agreement, “Affiliates” shall not include any “portfolio company” (as such term is customarily used among private equity investors)
that may be deemed to be an “Affiliate” of the Shareholder) the ability to exercise voting rights with respect to shares of Company Common Stock) Beneficially Owned by the Shareholder as of the applicable record date (together with any
Company Common Stock that the Shareholder may acquire after the date hereof, including pursuant to the Metavante Stock Purchase Right Agreement or the Shareholders Agreement (as hereinafter defined), the “Owned Shares”) (i) in
favor of the Merger, the execution and delivery by the Company of the Merger Agreement and the adoption and approval of the Merger Agreement and the terms thereof, in favor of each of the other actions contemplated by the Merger Agreement and in
favor of any action in furtherance of any of the foregoing (in each case whether or not recommended by the Board of Directors of the Company) and (ii) against (A) any Acquisition Proposal or any proposal relating to an Acquisition
Proposal, (B) any merger agreement or merger (other than the Merger Agreement and the Merger), consolidation, combination, material business transaction or legal or regulatory action, sale of assets, reorganization, recapitalization,
dissolution, liquidation or winding up of or by the Company or 

 3 
  

 
any of its Subsidiaries, or (C) any amendment of the Company’s articles of incorporation or by-laws that, in the case of each of the foregoing
clauses (A) through (C) would (1) impede, frustrate, prevent or nullify any provision of this Agreement, the Merger Agreement or the Merger, (2) result in a breach in any respect of any covenant, representation, warranty or any
other obligation or agreement of the Company under the Merger Agreement, or (3) change in any manner the voting rights of the Owned Shares. The Shareholder shall not commit or agree to take any action inconsistent with the foregoing. Except as
set forth in this Section 2.1, nothing in this Agreement shall limit the right of the Shareholder to vote in favor of, against or abstain with respect to any matter presented to the Company’s shareholders, including in connection with the
election of directors proposed by the Company or Parent or Merger Sub or by a third party not in connection with an Acquisition Proposal proposed by such third party. 
 2.2. No Solicitation. The Shareholder agrees that it shall not (and shall not permit any representative or Affiliate of the Shareholder to), directly or indirectly, (a) initiate, solicit, facilitate or
encourage (including by way of furnishing information), or take any other action designed to facilitate, any inquiries or proposals that, if consummated, would constitute an Alternative Transaction, or participate in any discussions or negotiations
regarding an Alternative Transaction or potential Alternative Transaction, or enter into any agreement regarding any Alternative Transaction, or (b) in any manner participate in a “solicitation” (as such term is used in the rules of
the SEC) of proxies or powers of attorney or similar rights to vote with respect to the voting of, any shares of Company Common Stock intended to facilitate any Acquisition Proposal. The Shareholder will immediately cease and cause to be terminated
any existing discussions or negotiations with any Persons conducted prior to the date of this Agreement with respect to any of the foregoing. 
 2.3. Restrictions on Transfer, Etc. Except as provided for herein, the Shareholder agrees from and after the date hereof not to (a) tender into any tender or exchange offer or otherwise directly or indirectly Transfer any Owned
Shares (or any rights, options, warrants or other derivative securities to acquire Company Common Stock), or (b) grant or agree to grant any proxy or power of attorney with respect to the Owned Shares, deposit the Owned Shares into a voting
trust, enter into a voting agreement or arrangement with respect to any of the Owned Shares or otherwise restrict the ability of the Shareholder freely to exercise all voting rights with respect thereto. Any action attempted to be taken in violation
of the preceding sentence will be null and void. The Shareholder authorizes Parent to request the Company to notify the Company’s transfer agent that there is a stop transfer order with respect to all of the Owned Shares and that this Agreement
places limits on the voting of the Owned Shares. 
 2.4. Proxies. The Shareholder hereby revokes any and all previous proxies granted
with respect to the Owned Shares. 
 2.5. Shareholder Capacity. Nothing contained in this Agreement shall restrict, limit or prohibit
any affiliate or representative of the Shareholder from exercising his or her fiduciary duties in his or her capacity solely as a director of the Company. 

 4 
  

 III            REPRESENTATIONS AND
WARRANTIES 
 3.1. Representations and Warranties of the Shareholder. The Shareholder represents and warrants to Parent, Merger
Sub and the Company as of the date of this Agreement and as of the date of any meeting of shareholders of the Company and as of the date of the execution of any written consent of the shareholders of the Company, as follows: 
 (a) The Shareholder has the requisite capacity and authority to execute and deliver this Agreement and to consummate the transaction contemplated hereby.
This Agreement has been duly and validly executed and delivered by the Shareholder and, assuming this Agreement constitutes a legal, valid and binding agreement of Parent, Merger Sub and the Company, constitutes a legal, valid and binding agreement
of the Shareholder enforceable by Parent, Merger Sub and the Company against the Shareholder in accordance with its terms, except as the same may be limited by bankruptcy, insolvency, reorganization, moratorium and similar Laws now or hereafter in
effect relating to creditors’ rights generally and subject to general principles of equity. 
 (b) The Shareholder is the record and
Beneficial Owner, free and clear of any Liens of the Owned Shares (which number of Owned Shares as of the date hereof is set forth in the second recital hereto) and any Owned Shares acquired by the Shareholder after the date hereof, and has full,
unrestricted and sole power to dispose of and vote all of, and has not granted any proxy inconsistent with this Agreement that is still effective or entered into any voting or similar agreement with respect to, the Owned Shares; provided, however,
the Owned Shares are subject to the Shareholders Agreement. The Owned Shares are the only voting securities or interests in the Company Beneficially Owned or held of record by the Shareholder and, except as provided in the Shareholders Agreement and
the Metavante Stock Purchase Right Agreement and except for the Owned Shares and the shares of and options for shares of Company Common Stock owned by or granted to affiliates of the Shareholder who are directors of the Company, the Shareholder and
its Affiliates do not Beneficially Own or have any right to acquire (whether currently, upon lapse of time, following the satisfaction of any conditions, upon the occurrence of any event or any combination of the foregoing), any shares of Company
Common Stock or any securities convertible into shares of Company Common Stock (including options to purchase Company Common Stock). 
 (c)
None of the execution and delivery of this Agreement by the Shareholder, the consummation by the Shareholder of the transactions contemplated hereby or compliance by the Shareholder with any of the provisions hereof (i) requires any consent or
other authorization, approval or permit of, or filing with or notification to, any Governmental Entity or any other Person by the Shareholder, except for (A) filings required under the securities laws, including Sections 13(d) and 16 of the
Exchange Act, (B) as contemplated by the Merger Agreement, and (C) any consents, approvals, filings or notices required under the HSR Act and the termination or expiration of any applicable waiting period thereunder, (ii) results in a
violation or breach of, or constitutes (with or without notice or lapse of time or both) a default (or gives rise to any third party right of termination, cancellation, material modification or acceleration) under any of the terms, conditions or
provisions of any Contract to which the Shareholder is a party or by which the Shareholder or any of the Shareholder’s properties or assets (including the Owned Shares) may be bound, (iii) violates any Order or Law applicable to the
Shareholder or any of the 

 5 
  

 
Shareholder’s properties or assets (including the Owned Shares), or (iv) results in a Lien upon any of the Shareholder’s properties or assets
(including the Owned Shares), except for violations, breaches, defaults or Liens as would not prevent, impede or delay the performance by the Shareholder of its obligations hereunder or impose any greater than nominal liability or obligation on the
Company or Parent or any Subsidiaries or Affiliates thereof. 
 (d) The Shareholder, as of the date hereof, is not engaged in discussions or
negotiations with any party with respect to any Acquisition Proposal. 
 IV            ADDITIONAL COVENANTS OF THE SHAREHOLDER 
 4.1.
Additional Shares. The Shareholder hereby agrees, while this Agreement is in effect, to promptly notify Parent in writing of the number of any additional shares of Company Common Stock or other securities of the Company or other derivative or
contractual arrangements with respect to which Beneficial Ownership is acquired by the Shareholder, if any, after the date hereof (and, for the avoidance of doubt, the Shareholder agrees that any such additional shares shall be, for purposes of this
Agreement, “Owned Shares”); provided that filings made by the Shareholder pursuant to Sections 13(d) and 16 of the Exchange Act shall constitute notice for purposes of this Section 4.1. 
 4.2. Disclosure. The Shareholder hereby authorizes Parent, Merger Sub and the Company to publish and disclose in any announcement or disclosure
required by the SEC and in the Joint Proxy Statement and the Form S-4 the Shareholder’s identity and ownership of the Owned Shares and the nature of the Shareholder’s obligation under this Agreement. 
 4.3. Non-Interference; Further Assurances. Subject to Section 2.5, the Shareholder shall not make any statements, publicly or privately,
involving one or more third parties, that are intended to be materially adverse to the Merger Agreement and the transactions contemplated by the Merger Agreement (including the Merger) or intended to cause such third parties to vote, or knowingly
encourage other Persons (including but not limited to Shareholder’s “portfolio companies”) to vote, in any manner inconsistent with the Shareholder’s obligations under Section 2.1; provided, however, that this
Section 4.3 shall in no event require the Shareholder to make any public or private statements to third parties regarding the Merger Agreement and the transactions contemplated by the Merger Agreement. The Shareholder agrees to execute and
deliver such additional documents and to take such further actions as necessary or reasonably requested by Parent or Merger Sub to comply with the rights and obligations set forth in this Agreement. 
 4.4. Shareholders Agreement. For the avoidance of doubt, effective as of the Effective Time, each of the Company and the Shareholder hereby waives
all rights it has under the Shareholders Agreement, dated as of November 1, 2007, between the Company and the Shareholder, as amended (the “Shareholders Agreement”), and the Shareholders Agreement shall be deemed terminated and
be of no further force or effect. The Company’s entry into this Agreement shall constitute the written request in advance by the Company’s Board of Directors to the Shareholder to enter into and comply with the terms of this Agreement, as
contemplated by Section 3.2(a) of the Shareholders Agreement. 

 6 
  

 V            TERMINATION 
 5.1. Termination. This Agreement shall automatically terminate and be of no further force or effect upon the earliest to occur of (i) the
date upon which the Merger Agreement shall have been terminated in accordance with its terms, (ii) the date upon which the Merger shall become effective or (iii) the date of any amendment, modification, change or waiver to the Merger
Agreement executed after the date hereof that results in a decrease in the Exchange Ratio (including any such decrease coupled with a replacement of such decreased amount with cash consideration) or the Merger Consideration. 
 5.2. Effect of Termination. Upon termination of this Agreement, except for any rights any party may have in respect of any breach by any other
party of its obligations hereunder, none of the parties hereto shall have any further obligation or liability hereunder. 
 VI            GENERAL 
 6.1. Notices. All notices shall
be in writing and shall be deemed given (i) when delivered personally, (ii) when telecopied (which is confirmed) or (iii) when dispatched by a nationally recognized overnight courier service to the parties at the following addresses
(or at such other address for a party as shall be specified by like notice): (a) if to the Shareholder, to the address set forth below the Shareholder’s name on the signature page hereto, and (b) if to Parent, Merger Sub or the
Company, in accordance with Section 9.4 of the Merger Agreement, or to such other Persons, addresses or facsimile numbers as may be designated in writing to each other party hereto by the Person entitled to receive such communication as
provided above. 
 6.2. No Third Party Beneficiaries. Except as specifically set forth herein, this Agreement is not intended to
confer any rights or remedies upon any Person other than the parties to this Agreement. 
 6.3. Governing Law. This Agreement and any
controversies arising with respect hereto shall be construed in accordance with and governed by the law of the State of Delaware (without regard to principles of conflict of laws that would apply the law of another jurisdiction). 
 6.4. Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other
authority to be invalid, void, unenforceable or against its regulatory policy, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or
invalidated. Upon such determination that any term, provision, covenant or restriction of this Agreement is invalid, void, unenforceable or against regulatory policy, the parties hereto shall negotiate in good faith to modify this Agreement so as to
effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible. 
 6.5. Assignment. The provisions of this Agreement shall be binding upon, inure to the benefit of and be enforceable by the parties hereto and
their respective successors and assigns; provided, however, that none of the parties hereto may assign, delegate or otherwise transfer any of its rights or obligations under this Agreement without the prior written consent of the other 

 7 
  

 
parties (provided that the Company’s consent shall only be needed with respect to any assignment of the Shareholder’s rights or obligations with
respect to Sections 4.4, 6.16 and 6.17) and any attempted assignment without such consent shall be null and void without effect; and provided, further, however, that Parent may assign its respective rights or obligations hereunder to any direct or
indirect wholly owned Subsidiary of Parent (or any successor thereto) without the prior written consent of the parties hereto. 
 6.6.
Interpretation. For the purposes of this Agreement, (i) words in the singular shall be held to include the plural and vice versa and words of one gender shall be held to include the other gender as the context requires, (ii) the
terms “hereof”, “herein”, and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of this Agreement, and Article,
Section, paragraph references are to the Articles, Sections, paragraphs to this Agreement unless otherwise specified, (iii) the word “including” and words of similar import when used in this Agreement shall mean “including,
without limitation,” unless the context otherwise requires or unless otherwise specified, (iv) the word “or” shall not be exclusive, (v) provisions shall apply, when appropriate, to successive events and transactions,
(vi) unless otherwise specified, all references to any period of days shall be deemed to be to the relevant number of calendar days. The Article, Section and paragraph headings contained in this Agreement are for reference purposes only and
shall not affect in any way the meaning or interpretation of this Agreement. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting or causing any instrument to
be drafted. References to a Person will refer to its predecessors and successors and permitted assigns. 
 6.7. Amendments. This
Agreement may not be amended, changed, supplemented or otherwise modified except by written agreement signed by Parent, Merger Sub, the Shareholder and the Company. 
 6.8. Waiver. The failure of any party to exercise any right, power or remedy provided under this Agreement or otherwise available in respect hereof at law or in equity, or to insist upon compliance by any other
party with such party’s obligations hereunder, and any custom or practice of the parties at variance with the terms hereof, shall not constitute a waiver by such party of such party’s right to exercise any such or other right, power or
remedy or to demand such compliance. 
 6.9. Fees and Expenses. Except as set forth in that certain letter agreement, dated the date
hereof, between the Shareholder and the Company, each party is responsible for its own fees and expenses (including the fees and expenses of financial consultants, investment bankers, accountants and counsel) in connection with the entry into of
this Agreement and the consummation of the transactions contemplated hereby. 
 6.10. Entire Agreement. This Agreement constitutes the
entire agreement and supersedes all other prior agreements, understandings, representations and warranties, both written and oral, among the parties to this Agreement with respect to the subject matter of this Agreement. 

 8 
  

 6.11. Remedies Cumulative. Except as otherwise provided in this Agreement, any and all remedies
expressly conferred upon a party to this Agreement will be cumulative with, and not exclusive of, any other remedy contained in this Agreement, at law or in equity. The exercise by a party to this Agreement of any one remedy will not preclude the
exercise by it of any other remedy. 
 6.12. Counterparts; Effectiveness; Execution. This Agreement may be executed in any number of
counterparts, all of which are one and the same agreement. This Agreement will become effective when each party to this Agreement has received counterparts signed by all of the other parties. This Agreement may be executed by facsimile signature by
any party and such signature is deemed binding for all purposes hereof, without delivery of an original signature being thereafter required. 
 6.13. Specific Performance. The parties hereby agree that irreparable damage to the other party would occur, damages would be difficult to determine and would be an insufficient remedy and no other adequate remedy would exist at law
or in equity, in each case in the event that any provision of this Agreement were not performed by the parties hereto in accordance with its specific terms or were otherwise breached. Each party hereby waives any defenses based on the adequacy of
any other remedy, whether at law or in equity, that might be asserted as a bar to the remedy of specific performance of any of the terms or provisions hereof or injunctive relief in any action brought by another party hereto. Accordingly, the
parties acknowledge and hereby agree that in the event of any breach by a party hereto of any of its covenants or obligations set forth in this Agreement, the other party shall be entitled (in addition to any other remedy that may be available at
law or in equity, including monetary damages) to obtain (i) a decree or order of specific performance to enforce the observance and performance of such covenant or obligation, and (ii) an injunction restraining such breach or threatened
breach. Any requirements for the securing or posting of any bond with such remedy are waived. 
 6.14. Submission to Jurisdiction. The
parties to this Agreement agree that any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated by this Agreement shall be brought
in any federal or state court located in the state of Delaware, and each of the parties hereby irrevocably consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and
irrevocably waives, to the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding brought in
any such court has been brought in an inconvenient forum. The parties to this Agreement agree that mailing of process or other papers in connection with any such action or proceeding in the manner provided in Section 6.1 or in such other manner
as may be permitted by applicable Laws, will be valid and sufficient service thereof. 
 6.15. Waiver of Jury Trial. Each party
acknowledges and agrees that any controversy which may arise under this Agreement is likely to involve complicated and difficult issues and, therefore, each such party irrevocably and unconditionally waives any right it may have to a trial by jury
in respect of any Action arising out of or relating to this Agreement or the transactions contemplated by this Agreement. Each party to this Agreement certifies and acknowledges that (a) no representative of any other party has represented,
expressly or otherwise, that such other 

 9 
  

 
party would not seek to enforce the foregoing waiver in the event of an Action, (b) such party has considered the implications of this waiver,
(c) such party makes this waiver voluntarily, and (d) such party has been induced to enter into this Agreement by, among other things, the mutual waivers and certifications in this Section 6.15. 
 6.16. Shareholders Agreement. The Company acknowledges that the execution and delivery of this Agreement by the Shareholder, the consummation by
the Shareholder of the transactions contemplated hereby or compliance by the Shareholder with any of the provisions hereof does not conflict with or otherwise violate the terms of the Shareholders Agreement including, but not limited to,
Section 3.2 thereof. 
 6.17. Antitrust Matters. Each of Parent, Merger Sub and the Company shall (a) cooperate with
Stockholder and its affiliates, including, without limitation, Warburg Pincus & Co., in connection with the filing by the Shareholder and/or its affiliates of any necessary documentation required to effect all approvals, clearances and
authorizations of all Governmental Entities pursuant to the HSR Act, including Notification and Report Forms required under the HSR Act, in connection with the transactions contemplated by this Agreement, the Merger Agreement (including the Merger),
the Parent Stock Purchase Right Agreement and/or the Parent Shareholders Agreement and (b) supply as promptly as practicable any additional information and documentary material that may be requested by such Governmental Entities. 
 [Rest of page intentionally left blank] 

 IN WITNESS WHEREOF, each party hereto has caused this Agreement to be signed as of the date first above
written. 
  

			
	FIDELITY NATIONAL INFORMATION SERVICES, INC.
		
	By:	 	 /s/ Lee A. Kennedy

	Name:	 	Lee A. Kennedy
	Title:	 	President and Chief Executive Officer

 [SIGNATURE PAGE TO SUPPORT AGREEMENT] 

			
	CARS HOLDINGS, LLC
		
	By:	 	 /s/ Ronald D. Cook

	Name:	 	Ronald D. Cook
	Title:	 	Executive Vice President, General
Counsel and Corporate Secretary

 [SIGNATURE PAGE TO SUPPORT AGREEMENT] 

			
	 METAVANTE TECHNOLOGIES, INC.
 (Solely for the
purpose of Sections 4.4, 6.16 and 6.17)

		
	By:	 	 /s/ Donald W. Layden, Jr.

	 Name:
	 	 Donald W. Layden, Jr.

	 Title:
	 	 Senior Executive Vice President

 [SIGNATURE PAGE TO SUPPORT AGREEMENT] 

			
	WPM, L.P.
		
	By:	 	WPM GP, LLC, its general partner
		
	By:	 	 /s/ James Neary

	Name:	 	James Neary
	Title:	 	Managing Director

  

	
	Notice Address:
	
	c/o Warburg Pincus & Co.
	466 Lexington Avenue
	New York, NY 10017
	Attn: James Neary
	Facsimile: (212) 878-9351

 with a copy to (which shall not constitute notice): 
  

			
	Willkie Farr & Gallagher LLP
	787 Seventh Avenue
	New York, NY 10019
	Attn:	 	Steven J. Gartner, Esq.
		 	Robert T. Langdon, Esq.

			
	Facsimile: (212) 728-8111

 [SIGNATURE PAGE TO SUPPORT AGREEMENT]Stock Purchase Right Agreement

 Exhibit 10.2 
 FIDELITY NATIONAL INFORMATION SERVICES, INC. 
 STOCK PURCHASE RIGHT AGREEMENT 
 Stock Purchase Right Agreement, dated as of March 31, 2009 (as it may be amended from time to time, this “Agreement”) among
Fidelity National Information Services, Inc., a Georgia corporation (the “Company”), WPM, L.P., a Delaware limited partnership (the “Investor”), and solely for the purpose of Sections 5.1, 5.8 and 5.10, Metavante
Technologies, Inc., a Wisconsin corporation (“Metavante”). 
 WHEREAS, concurrently with the execution of this Agreement,
the Company, Cars Holdings, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of the Company (“Merger Sub”), and Metavante are entering into an Agreement and Plan of Merger (“Merger
Agreement”), which provides, subject to Section 1.1 of the Merger Agreement, for the merger (the “Merger”) of Metavante with and into Merger Sub, pursuant to which all of the outstanding capital stock of Metavante will
be converted into the right to receive shares of capital stock of the Company, as set forth in the Merger Agreement; 
 WHEREAS, as of the
date hereof, Investor owns shares of common stock of Metavante and is a party to an Amended and Restated Stock Purchase Right Agreement, dated as of August 21, 2008, between Metavante and Investor (the “Metavante Stock Purchase Right
Agreement”); 
 WHEREAS, as a condition to, among other things, Investor’s willingness to enter into and perform its
obligations under that certain Support Agreement, dated as of the date hereof, among the Company, Merger Sub, Investor and Metavante, the Company has agreed to enter into this Agreement and the Shareholders Agreement; and 
 WHEREAS, upon consummation of the Merger, the Investor will own shares of common stock, par value $0.01 per share, of the Company (the “Common
Shares”), and the Investor and the Company are entering into this Agreement in furtherance of that connection; 
 WHEREAS, except
for Sections 2, 4.9, 5.1 through 5.8, 5.10 and 5.11, which shall be effective upon the date set forth above, this Agreement shall be effective as of the date of the effective time of the Merger pursuant to the terms of the Merger Agreement (the
“Effective Time”); and 
 WHEREAS, the actions contemplated herein on behalf of each of the Company and Investor have been
duly and validly authorized by all necessary action and no other proceedings on the part of the Company or Investor are necessary to consummate the actions contemplated herein. 
 NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties do hereby agree as follows: 
 1. Purchase Right. Upon the terms and subject to the conditions set forth in
this Agreement, the Company hereby grants to the Investor the right to purchase from the Company the Subject Shares at the Purchase Prices; provided, however, that notwithstanding anything to the contrary contained in this Agreement,
the total number of Subject Shares that may be 

 
purchased under this Agreement shall equal one-third of the aggregate number of Common Shares that may be issued under the Subject Employee Options, subject
to reduction, if any, pursuant to Section 3.1(b) hereof. As of the date hereof, there were (i) options to purchase 6,827,536 shares of common stock of Metavante outstanding that (subject to reduction pursuant to Section 3.1(b) of the
Metavante Stock Purchase Right Agreement prior to the Effective Date) will be converted into Subject Employee Options pursuant to the terms of the Merger Agreement (such options, the “Applicable Metavante Options”). Within five
business days after the determination of the number of Subject Employee Options into which the Applicable Metavante Options are convertible pursuant to the Merger Agreement (such date of determination to be as soon as reasonably practicable
after the Closing Date), the Company shall deliver to Investor a schedule setting forth, with respect to each Subject Employee Option into which the Applicable Metavante Options were converted pursuant to the Merger Agreement, the expiration
date, exercise price and number of Common Shares underlying such Subject Employee Option. 
 2. Expiration Date; Effectiveness.
Subject to Section 5.9, in no event may the Purchase Right (as defined in Section 3.2(a)) be exercised, in whole or in part, after the earlier of (i) the date that is forty-five days after the Quarterly Notice (as defined herein) is
given in respect of the calendar quarter in which all Subject Employee Options expire, (ii) the date that all Subject Shares (as they may have been reduced pursuant to Sections 3.1(b) or 3.2(b)) have been purchased by the Investor or
(iii) ten years from November 1, 2007, unless the Board shall extend the expiration date of any of the Subject Employee Options beyond the end of such ten-year period, in which case the Purchase Right shall be similarly extended (the
“Expiration Date”). Except with respect to this Section 2, Section 4.9, Sections 5.1 through 5.8, Section 5.10 and Section 5.11 which shall be effective on the date first set forth above, this Agreement will be
automatically effective as of the Effective Time and will continue in effect thereafter until the Expiration Date. In the event the Merger Agreement is terminated in accordance with its terms prior to the Closing Date, this Agreement shall
automatically thereafter terminate and be of no further force and effect; provided, however, this Section 2 and Section 5.10 shall remain in effect pursuant to its terms and Section 5.1 shall remain in effect with respect to Investor
and Metavante. 
 3. Exercise of Purchase Right. 
 3.1. Quarterly Notice and Reduction of Right. 
 (a) No later than the last day of each
month following the end of each calendar quarter prior to the Expiration Date, the Company shall give the Investor a notice setting forth the following: (i) the aggregate number of Common Shares issued during such quarter upon the exercise of
Subject Employee Options, (ii) the aggregate exercise price of such Subject Employee Options for such Common Shares, and (iii) the aggregate number and exercise price of Subject Employee Options that expired unexercised or were forfeited
during such quarter (the “Quarterly Notice”). The Quarterly Notice shall be accompanied by a schedule setting forth, in the form of tranches of the same exercise dates and exercise prices, all unexercised Subject Employee Options as
of the end of such quarter. 
  

 -2- 

 (b) The Subject Shares shall be automatically reduced by a number equal to one-third of
the Common Shares issuable (x) under Subject Employee Options that expire unexercised or are forfeited and (y) under Out of the Money Options as provided in Sections 3.2(a) and 3.2(c). 
 3.2. Method of Exercise. 
 (a) The Investor shall have a purchase right (including the right to purchase via a
Cash Payment, the “Purchase Right”) to purchase a whole number of Common Shares equal to the difference (rounded down to the nearest whole share) between (i) one-third of the aggregate number of Common Shares issued under the
Subject Employee Options during each calendar quarter the exercise prices of which equal or are less than the Fair Market Value as of the date of exercise of the Purchase Right for such Common Shares (each such Subject Employee Option, an
“In-the-Money Option”; but for clarity, when determining such “In-the-Money Options”, the reference to “one-third” in this clause (i) shall be omitted), and (ii) the quotient of (A) one-third of
the aggregate exercise prices of such In-the-Money Options for such Common Shares, in each case as specified in the Quarterly Notice with respect to such quarter (it being understood that this number shall not be reduced for any such Common Shares
that are withheld from employees to pay the exercise price of such Subject Employee Options, or any withholding taxes due, pursuant to net vesting settlement and similar provisions) (such number as derived in this subclause (A), the
“Exercise Price Equivalent”), divided by (B) the Fair Market Value of a Common Share, determined as of the close of business on the business day immediately before the date of purchase, which date shall also be deemed the date
of exercise of the Purchase Right for purposes of determining the In-the-Money Options and Out of the Money Options, for a Purchase Price per share equal to $0.01. Such purchase shall, subject to Section 5.9, take place 45 days following the
date the Quarterly Notice is given (or the first business day following such 45th day, if such day is not a business day). Following the Quarterly
Notice and prior to such date of purchase, the Investor may in lieu of the foregoing purchase right, deliver to the Company a notice (the “Cash Payment Notice”) electing to purchase by a Cash Payment a number of Common Shares equal
to one-third of the aggregate number of Common Shares issued under the In-the-Money Options for an aggregate Purchase Price equal to the Exercise Price Equivalent, in which case the Cash Payment shall be made on the same date the Cash Payment Notice
is delivered to the Company; provided that, if the Investor exercises its right to make the Cash Payment, such right shall also be included in the term “Purchase Right” for purposes of this Agreement. Upon the purchase of any Common
Shares pursuant to this Section 3.2(a) or Section 3.3, the number of Subject Shares remaining shall be reduced by the number of Common Shares that would have been purchased assuming the Investor had purchased using the Cash Payment. The
Subject Shares shall also be reduced by a number equal to one-third of the number of Common Shares issued during each calendar quarter pursuant to Out of the Money Options. 
 (b) In the event the Investor sells, transfers, assigns or otherwise disposes of (whether by operation of law or otherwise) (but only in
the event that the Purchase Right is not accelerated under Section 3.2(c) in connection with such event), to 

  

 -3- 

 
a third party that is not an affiliate of the Investor or distributes to its limited partners (collectively, “Transfers”), any of the Common
Shares it acquired pursuant to the terms of the Merger Agreement, but not any Common Shares that it thereafter acquired in excess of such Common Shares (it being understood that in connection with any such sale, transfer, assignment or disposition
the Investor shall be deemed to have first sold, transferred, assigned or disposed of the Common Shares it acquired pursuant to the terms of the Merger Agreement until the Investor has sold, transferred, assigned or disposed of all such Common
Shares), it may exercise the Purchase Right for a whole number of Common Shares equal to the difference (rounded down to the nearest whole share) between (i) the number of applicable Acceleration Subject Shares, and (ii) the quotient of
(A) the related Acceleration Purchase Price, divided by (B) the Fair Market Value of a Common Share, determined as of the date the Acceleration Notice is given, for a Purchase Price per share equal to $0.01, by delivering to the Company an
irrevocable exercise notice within 10 days of such sale (the “Acceleration Notice”). The Acceleration Notice shall set forth the number of Common Shares that have been sold by the Investor and the dates of sales thereof and shall
certify that such Acceleration Notice is being given in accordance with Section 3.2(b), and shall specify whether, in lieu of the foregoing Purchase Right, the Investor wishes to elect to purchase by a Cash Payment the number of applicable
Acceleration Subject Shares for an amount equal to the Acceleration Purchase Price. Within 10 business days of receiving the Acceleration Notice, the Company shall give the Investor notice (the “Acceleration Details Notice”) of the
Acceleration Purchase Price applicable to the Acceleration Notice as well as the Company’s calculation of the number of Acceleration Subject Shares being purchased by the Investor pursuant to such Acceleration Notice. In the event that Investor
elects to pay the Acceleration Purchase Price in cash, it shall deliver the Acceleration Purchase Price specified in the Acceleration Notice no later than three days following the giving of such Acceleration Details Notice. Upon the purchase of any
Acceleration Subject Shares pursuant to this Section 3.2(b), the number of Subject Shares remaining shall be reduced by the number of Acceleration Subject Shares so purchased. 
 (c) Immediately prior to an all-cash merger or other business combination involving the Company in which the Common Shares are converted
into the right to receive only cash in exchange for such Common Shares, the Purchase Right shall automatically be deemed exercised for the number of Common Shares equal to the difference (rounded down to the nearest whole share) between (i) all
Subject Shares then still subject to the Purchase Right and (ii) the quotient of (A) the related Acceleration Purchase Price, divided by (B) the Fair Market Value of a Common Share, determined as of three business days before the date
of such acceleration, for a Purchase Price per share equal to $0.01. The Subject Shares shall be reduced by a number equal to one-third of the number of Common Shares subject to Out of the Money Options as of the date of an acceleration pursuant to
this Section 3.2(c). 
 (d) The Purchase Right may be exercised by the Investor solely as and to the extent expressly set
forth in this Section 3.2. In no event may the Purchase Right be exercised after it terminates as set forth in Section 2. No certificate representing a Common Share shall be delivered to the Investor until the full purchase price therefore

  

 -4- 

 
has been paid. Notwithstanding anything to the contrary contained in this Agreement, the Company shall have no obligation to issue any fraction of a Common
Share under this Agreement and all of such fractional shares shall be disregarded. 
 3.3. Metavante Stock Purchase Right Agreement. In addition to the rights set forth in this Agreement, in connection with the first Quarterly Notice required to be delivered by the Company following the Closing Date, the Company shall
deliver to the Investor a schedule setting forth the aggregate Closing Metavante Subject Shares, including (i) a computation of the In-the-Money Options (as defined in the Metavante Stock Purchase Right Agreement) and (ii) substantially
the same information regarding the Closing Metavante Subject Shares as the Company is required to deliver in the Quarterly Notice. In addition to any Purchase Rights that the Investor has related to such first Quarterly Notice, Investor shall have a
right (the “Metavante Purchase Right”) to purchase the Closing Metavante Subject Shares for a cash purchase price per share equal to $0.01; provided, however, in lieu of the foregoing purchase right, Investor may
deliver to the Company a notice electing to purchase by a Cash Payment one-third of the aggregate number of Metavante In-the-Money Option Shares for an aggregate purchase price equal to one-third of the aggregate exercise prices of such Metavante
In-the-Money Option Shares. Such purchase shall, subject to Section 5.9, take place 45 days following the date the first Quarterly Notice is given (or the first business day following such 45th day, if such day is not a business day). Exhibit A hereto sets forth, for illustrative purposes only, an example of the computation of the Metavante Purchase Right pursuant
to this Section 3.3. 
 4. Additional Terms and Conditions of Purchase Right. 
 4.1. Nontransferability of Purchase Right. The Purchase Right and the Metavante Purchase Right are exercisable only by the Investor. Neither the
Purchase Right nor the Metavante Purchase Right may be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process. Any
attempt to so sell, transfer, assign, pledge, hypothecate, encumber or otherwise dispose of the Purchase Right or the Metavante Purchase Right, shall be null and void. 
 4.2. Investment Representation. 
 (a) The Investor hereby represents and warrants that
(a) any Common Shares purchased upon exercise of either of the Purchase Right or the Metavante Purchase Right will be purchased for investment and not with a view to the distribution thereof within the meaning of the Securities Act of 1933, as
amended (the “Securities Act”), unless such purchase has been registered under the Securities Act and any applicable state securities laws; (b) any subsequent sale of any such shares shall be made either pursuant to an
effective registration statement under the Securities Act and any applicable state securities laws, or pursuant to an exemption from registration under the Securities Act and such state securities laws; and (c) if requested by the Company, the
Investor shall submit a written statement, in form reasonably satisfactory to the Company, to the effect that such representation (x) is true and correct as of the date of purchase of any shares hereunder or (y) is true and correct as of
the date of any sale of any such shares, as applicable. 
  

 -5- 

 (b) All Common Shares issued under this Agreement and the shares issued in connection
with the Metavante Purchase Right shall bear the legend specified in Section 6.3 of the Shareholders Agreement only for the time period specified in such Section 6.3. 
 4.3. Adjustment. In the event of any adjustment (i) in the Common Shares issuable upon exercise of Subject Employee Options or the Metavante
Purchase Right or (ii) to the terms of any of the Subject Employee Options, including the exercise prices, in each case including as a result of stock split, stock dividend, recapitalization, reorganization, merger, consolidation, combination,
exchange of shares, liquidation, spin-off or other similar change in capitalization or event (for the avoidance of doubt, other than the transactions contemplated by the Merger Agreement), the Subject Shares and the shares issuable in connection
with the Metavante Purchase Right and the terms and conditions thereof (including without limitation the Purchase Price thereof) shall be equitably adjusted by the Board in the same manner as the Subject Employee Options. 
 4.4. Compliance with Applicable Law. The Purchase Right and the Metavante Purchase Right are subject to the condition that if the listing,
registration or qualification of the Subject Shares or the shares issuable in connection with the Metavante Purchase Right upon any securities exchange or under any law, or the consent or approval of any governmental body, or the taking of any other
action is necessary or reasonably desirable as a condition of, or in connection with, the purchase or delivery of Subject Shares or the shares issuable in connection with the Metavante Purchase Right, the Purchase Right or the Metavante Purchase
Right, as applicable, may not be exercised, in whole or in part, unless such listing, registration, qualification, consent or approval shall have been effected or obtained. The Company and the Investor agree to use reasonable efforts to promptly
effect or obtain any such listing, registration, qualification, consent or approval. The Company represents and warrants that none of the execution and delivery of this Agreement by the Company, the consummation by the Company of the transactions
contemplated hereby or compliance by the Company with any of the provisions hereof requires any listing, registration or qualification of the Subject Shares or the shares issued in connection with the Metavante Purchase Right upon any securities
exchange or under any law, and that no consent or approval of any governmental body, or the taking of any other action is necessary as a condition of, or in connection with, the purchase or delivery of Subject Shares or the shares issuable in
connection with the Metavante Purchase Right by the Investor. 
 4.5. Delivery of Certificates. Upon the exercise of the Purchase
Right or the Metavante Purchase Right, as applicable, in whole or in part, the Company shall deliver or cause to be delivered one or more certificates representing the number of shares purchased against full payment therefore, subject to
Section 4.2(b). 
 4.6. Purchase Right Confers No Rights as Shareholder. The Investor shall not be entitled to any privileges of
ownership with respect to Subject Shares or the shares issuable in connection with the Metavante Purchase Right unless and until purchased and delivered upon the exercise of the Purchase Right or the Metavante Purchase Right, as applicable, in whole
or in part, and the Investor becomes a shareholder of record with respect to such delivered shares; and 

  

 -6- 

 
the Investor shall not be considered a shareholder of the Company with respect to any such shares not so purchased and delivered previously. 
 4.7. Company to Reserve Shares. The Company shall at all times prior to the expiration or termination of each of the Purchase Right and the
Metavante Purchase Right reserve and keep available, either in its treasury or out of its authorized but unissued Common Shares, the full number of shares subject from time to time to the Purchase Right and the Metavante Purchase Right. 

4.8. Shareholders Agreement. Any Common Shares issued upon exercise of the Purchase Right and all Common Shares issuable upon exercise of the
Metavante Purchase Right shall be subject to the provisions of the Shareholders Agreement, and shall be shares of “Common Stock” that are “Beneficially Owned” by Investor for purposes of the Shareholders Agreement. Without
limiting the generality of the foregoing, such Common Shares issued upon exercise of the Purchase Right and all Common Shares issued upon exercise of the Metavante Purchase Right shall be subject to (i) the registration rights provisions of
Article II of the Shareholders Agreement, (ii) the transfer restriction provisions of Section 3.1 of the Shareholders Agreement, and (iii) the provisions of Section 6.3 of the Shareholders Agreement only for the time period
specified in such Section 6.3. 
 4.9. Defined Terms. Capitalized terms used in this Agreement have the following meanings:

 “Acceleration Purchase Price” shall mean with respect to any Acceleration Subject Shares, one-third of the aggregate exercise price
of the Subject Employee Options to the extent used in determining such Acceleration Subject Shares. 
 “Acceleration Subject Shares”
shall mean (x) in the case of Section 3.2(b) a number of Common Shares equal to one-third of a percentage of the Reference Common Shares that is equal to the percentage of the Common Shares transferred by the Investor as contemplated by
Section 3.2(b) and in respect of which an Acceleration Notice had not been delivered previously, and (y) in the case of Section 3.2(c) a number of Common Shares equal to one-third of all Common Shares subject to then outstanding
Subject Employee Options the exercise prices of which are equal to or are less than the Fair Market Value as of the date of an acceleration pursuant to Section 3.2(c). 
 “Board” shall mean the Board of Directors of the Company, excluding the Investor Designee (as defined in the Shareholders Agreement). 
 “Cash Payment” shall mean a wire transfer of immediately available funds to such account as the Company may specify from time to time.

 “Closing Date” shall mean the date of the Effective Time of the Merger pursuant to the Merger Agreement. 
  

 -7- 

 “Closing Metavante Subject Shares” shall be determined by reference to the Closing Date and shall
be equal to the number of shares of Common Shares equal to the sum (rounded down to the nearest whole share number) obtained by adding (A) any Subject Shares (as defined in the Metavante Stock Purchase Right Agreement) that, but for
Section 5.10, the Investor would have had a right to purchase as a result of a Quarterly Notice (as defined in the Metavante Stock Purchase Right Agreement) that Metavante would have been required to give to the Investor, including, without
limitation, any Quarterly Notice (as defined in the Metavante Stock Purchase Right Agreement) Metavante would have been required to give to the Investor assuming the one month period set forth in the Metavante Stock Purchase Right Agreement had
expired prior to the Closing Date, but that the Investor did not exercise on or prior to the Closing Date, as contemplated by Section 5.10, plus (B), without duplication of the time period set forth in the preceding clause (A), the number of
Subject Shares (as defined in the Metavante Stock Purchase Right Agreement) the Investor could purchase if Metavante was obligated to determine, as of the Closing Date, the Investor’s Purchase Right (as defined in the Metavante Stock Purchase
Right Agreement) for the time period beginning on the first day of the most recent calendar quarter and ending on and including the Closing Date; provided, however, in calculating the number of Subject Shares (as defined in the
Metavante Stock Purchase Right Agreement) for the purposes of clause (A) and (B) above, the number of Common Shares (as defined in the Metavante Stock Purchase Right Agreement) obtained in respect of clause (i) of Section 3.2(a)
of the Metavante Stock Purchase Right Agreement shall first be multiplied by the Exchange Ratio (as defined in the Merger Agreement) prior to subtracting the number obtained in clause (ii) of Section 3.2(a) of the Metavante Stock Purchase
Right Agreement. For purposes of determining the Closing Metavante Subject Shares, (i) all computations and other determinations shall be made as of the Closing Date, including, without limitation, the determination of Fair Market Value (as
defined in the Metavante Stock Purchase Right Agreement), In-the-Money Options (as defined in the Metavante Stock Purchase Right Agreement) and Out of the Money Options (as defined in the Metavante Stock Purchase Right Agreement) and (ii) all
time periods regarding exercise of the Investor’s rights with respect to such Closing Metavante Subject Shares under the Metavante Stock Purchase Right Agreement shall be disregarded. 
 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar federal statute and the rules and regulations
thereunder, as in effect from time to time. 
 “Fair Market Value” shall mean the closing transaction price of a Common Share as
reported in the New York Stock Exchange Composite Transactions (or the equivalent reporting system for any other national securities exchange on which the Common Shares are primarily listed) on the date as of which such value is being determined or,
if there shall be no reported transactions for such date, on the next preceding date for which transactions were reported; provided, however, that if the Common Shares are not listed on any national securities exchange, the Fair Market
Value may be determined by the Board by whatever means or method as the Board, in the good faith exercise of its discretion, shall at such time deem appropriate. 
 “Metavante In-the-Money Option Shares” shall be determined by reference to the Closing Date and shall be equal to the number of shares of Common Shares equal to the product (rounded down to the nearest whole share
number) obtained by multiplying (A) the Exchange Ratio (as defined in the Merger Agreement) by (B) one-third of the aggregate number of shares 

  

 -8- 

 
of common stock of Metavante issued pursuant to all of the In-the-Money Options (as defined in the Metavante Stock Purchase Right Agreement; but for clarity,
when determining such “In-the-Money Options”, the reference to “one-third” in Section 3.2(a) of such Metavante Stock Purchase Right Agreement shall be omitted) included in the determination of the Closing Metavante Subject
Shares. 
 “Out of the Money Options” shall mean (x) in the case of Section 3.2(a), Subject Employee Options the exercise
prices of which are greater than the Fair Market Value as of the date of exercise of the Purchase Right for such Common Shares, and (y) in the case of Section 3.2(c), Subject Employee Options the exercise prices of which are greater than
the Fair Market Value as of the date of an acceleration pursuant to such Section 3.2(c). 
 “Purchase Prices” shall mean the
purchase prices for which the Investor may purchase Subject Shares hereunder. 
 “Reference Common Shares” shall mean, as of any time
of determination, the Subject Shares subject to those Subject Employee Options (i) that are outstanding, unexercised and vested, (ii) the exercise prices of which equal or are less than the Fair Market Value as of such date, (iii) not
previously used in determining the Acceleration Subject Shares in connection with any Acceleration Notice, and (iv) have the earliest grant dates (when compared to other Subject Employee Options that meet the specifications in clause
(i) – (iii) immediately above). 
 “Shareholders Agreement” shall mean that certain Shareholders Agreement, dated as
of the date hereof, among the Company, the Investor and any other Shareholders (as defined therein) that become a party thereto, as amended from time to time. 
 “Subject Employee Options” shall mean the options to acquire shares of common stock of Metavante that are subject to the Metavante Stock Purchase Right Agreement immediately prior to the Effective Time of the Merger,
which options are, pursuant to the terms set forth in the Merger Agreement, being converted into options to acquire Common Shares of the Company in connection with the Merger. The number of Subject Employee Options, if determined as of the date
hereof after giving effect to the Exchange Ratio (as defined in the Merger Agreement), is 9,217,173, and such number shall only be reduced prior to the Effective Time of the Merger in accordance with Section 3.1(b)(x) of the Metavante Stock
Purchase Right Agreement. 
 “Subject Shares” shall mean the Common Shares issuable pursuant to Section 3 hereof. 
 5. Miscellaneous Provisions. 
 5.1.
Successors. This Agreement shall be binding upon and inure to the benefit of the Investor, the Company and the successors and assigns of the Company and with respect to Section 5.10, the successors and assigns of Metavante. The Investor
may not assign any of its rights or obligations under this Agreement, whether by operation of law or otherwise. Nothing in this Agreement, express or implied, is intended to or shall confer upon any other person any right, benefit or remedy of any
nature whatsoever under or by reason of this Agreement. 
  

 -9- 

 5.2. Notices. All notices and other communications hereunder shall be in writing and shall be
deemed duly given (a) on the date of delivery if delivered personally, (b) upon confirmation of receipt if delivered by telecopy or telefacsimile, (c) on the first business day following the date of dispatch if delivered by a
recognized next-day courier service, or (d) on the date received if delivered by registered or certified mail, return receipt requested, postage prepaid. All notices hereunder shall be delivered as set forth below, or pursuant to such other
instructions as may be designated in writing by the party to receive such notice: 
 If to the Company, to it at: 

Fidelity National Information Services, Inc. 
 601 Riverside Ave. 
 Jacksonville, Florida 32204 
 Attention: Executive Vice President and General Counsel 
 Facsimile: (904) 357-1005 
 and 
 Fidelity National Information Services, Inc. 
 4050 Calle Real, Suite 210 
 Santa Barbara, CA 93110 
 Attention: Executive Vice President, Legal 
 Facsimile: (805) 696-7831 
 with a copy to (which shall not constitute notice): 
 Wachtell, Lipton, Rosen & Katz

 51 West 52nd Street 
 New York, New York 10019 

			
	 Attention:
	 	Edward D. Herlihy, Esq.
		 	Lawrence S. Makow, Esq.
		 	Matthew M. Guest, Esq.

 Facsimile: (212) 403-2000 
 If to Investor, to it at: 
 WPM, L.P. 
 c/o Warburg Pincus & Co. 
 466 Lexington Avenue 
 New York, New York 10017 
 Attention: James Neary 
 Facsimile: (212) 878-9351 
 with a copy to (which shall not constitute notice): 
 Willkie Farr & Gallagher LLP

 787 Seventh Avenue 
  

 -10- 

 New York, New York 10019 

			
	 Attention:
	 	Steven J. Gartner, Esq.
		 	Robert T. Langdon, Esq.

 Facsimile: (212) 728-8111 
 If to Metavante, to it at: 
 Metavante Technologies, Inc. 
 4900 West Brown Deer Road 
 Milwaukee, Wisconsin 53223 
 Attention: Chief Executive Officer 
 Facsimile: (414) 362-1775 
 and 
 Metavante Technologies, Inc. 
 4900 West Brown Deer Road 
 Milwaukee, Wisconsin 53223 
 Attention: General Counsel 
 Facsimile: (414) 362-1775 
 with a copy to (which shall not constitute notice): 
 Kirkland & Ellis LLP 
 Citigroup Center 
 153 E.
53rd Street 
 New York,
New York 10022 

			
	 Attention:
	 	Stephen Fraidin, Esq.
		 	Jeffrey Symons, Esq.

 Facsimile: (212) 446-4900 
 and 
 Quarles & Brady LLP 
 411 E. Wisconsin Avenue 
 Milwaukee, WI 53202 

			
	 Attention:
	 	Conrad G. Goodkind, Esq.
		 	Walter J. Skipper, Esq.

 Facsimile: (414) 978-8976 
 or to such other persons or addresses as may be designated in writing by the party to receive such notice as provided above. 
 5.3. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (without giving effect
to choice of law principles thereof). 
  

 -11- 

 5.4. Consent to Jurisdiction. Each of Investor and the Company irrevocably agrees that any legal
action or proceeding with respect to this Agreement, any provision hereof, the breach, performance, validity or invalidity hereof or for recognition and enforcement of any judgment in respect hereof brought by another party hereto or its successors
or permitted assigns may be brought and determined in any federal or state court located in the State of Delaware, and each of Investor and the Company hereby irrevocably submits with regard to any such action or proceeding for itself and in respect
to its property, generally and unconditionally, to the exclusive jurisdiction of the aforesaid courts. Each of Investor and the Company hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise,
in any action or proceeding with respect to this Agreement, any provision hereof or the breach, performance, enforcement, validity or invalidity hereof, (i) any claim that it is not personally subject to the jurisdiction of the above-named
courts for any reason other than the failure to lawfully serve process, (ii) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice,
attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (iii) to the fullest extent permitted by applicable laws, that (A) the suit, action or proceeding in any such court is
brought in an inconvenient forum, (B) the venue of such suit, action or proceeding is improper and (C) this Agreement, or the subject matter hereof, may not be enforced in or by such courts. 
 5.5. Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (a) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, TO IT THAT SUCH OTHER PARTY WOULD NOT, IN THE
EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (b) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (c) EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND (d) EACH PARTY HAS BEEN INDUCED TO ENTER INTO
THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 5.5. 
 5.6. Counterparts. This Agreement
may be executed in counterparts each of which shall be deemed an original and which together shall constitute one and the same instrument. 
 5.7. Descriptive Headings. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement. 
 5.8. Amendments and Waivers. The provisions of this Agreement may be amended or waived only upon the prior written consent of the Company (to the extent approved by a majority of Independent Directors,
excluding the Investor Designee, each as defined in the Shareholders Agreement) and Investor; provided, however, that with respect to any amendments to this 

  

 -12- 

 
Section 5.8 or Sections 5.1 or 5.10 prior to the Closing Date, the prior written consent of Metavante shall also be required. 
 5.9. Section 16 Matters. The exercise dates set forth herein applicable to the Investor shall, at the request of the Investor, automatically
be extended as necessary to avoid liability, if any, to the Investor under Section 16 of the Exchange Act; provided, however, in the event the Investor requests that such exercise date be extended, all computations and other
determinations shall be made as of the date on which the exercise period (without giving effect to any extension pursuant to this Section 5.9) would have otherwise occurred. For as long as the Investor is entitled to appoint the Investor
Designee pursuant to the terms of the Shareholders Agreement, the Board of Directors of the Company, or a committee thereof consisting of non-employee directors (as such term is defined for purposes of Rule 16b-3 under the Exchange Act), shall, if
requested by the Investor, and to the extent then permitted under applicable law, adopt resolutions and otherwise use reasonable efforts to cause any acquisition from the Company of Common Shares issued pursuant to this Agreement and Common Shares
issuable in connection with the Metavante Purchase Right or dispositions to the Company of Common Shares issued pursuant to this Agreement or Common Shares issuable in connection with the Metavante Purchase Right to be exempt under Rule 16b-3 under
the Exchange Act. 
 5.10. Suspension of Rights under Metavante Stock Purchase Right Agreement; Amendment and Termination of Metavante
Stock Purchase Right Agreement. 
 (a) Investor and Metavante agree that from and
after the date hereof the rights and obligations of Investor and Metavante under the Metavante Stock Purchase Right Agreement shall be suspended and in lieu of the Investor’s purchase rights under such Metavante Stock Purchase Agreement,
Investor shall be entitled to exercise the Metavante Purchase Right at the time and on the terms set forth in Section 3.3 herein. In the event this Agreement is terminated pursuant to the last sentence of Section 2 herein, Investor and
Metavante, in good faith, shall determine the purchase rights Investor would have had under the Metavante Stock Purchase Right Agreement (assuming any Quarterly Notices (as defined in such Metavante Stock Purchase Right Agreement) were delivered to
Investor on the date that is 15 days following the end of each calendar quarter during which Investor’s purchase rights were suspended pursuant to this Section 5.10 and assuming Investor would have exercised such purchase rights 45 days
following the date such Quarterly Notice is assumed to have been given (or the first business day following such 45th day, if such day is not a
business day)), and Investor shall have 45 days following the date of termination of this Agreement to exercise such purchase rights for the purchase price determined pursuant to the Metavante Stock Purchase Right Agreement and from and after the
date of termination of this Agreement, the Metavante Stock Purchase Right Agreement shall remain in full force and effect in accordance with its terms and Investor’s and Metavante’s respective rights and obligations shall no longer be
deemed to be suspended. Investor and Metavante agree that the provisions of Sections 4.9 and 5.1 through and including 5.7 shall govern this Section 5.10. 
 (b) Effective as of the date hereof, each of Metavante and Investor hereby agrees that Section 3.2(c) of the Metavante Stock Purchase Right Agreement be, and hereby is, amended and restated in its entirety as
follows: 
  

 -13- 

 “Subject to the proviso below, immediately prior to (i) any event causing the simultaneous
acceleration of the vesting, or automatic exercise, of all the Subject Employee Options or (ii) a merger or other business combination involving the Company in which the Common Shares are converted into the right to receive cash in exchange for
such Common Shares, the Purchase Right shall automatically be deemed exercised for the number of Subject Shares equal to the difference (rounded down to the nearest whole share) between (i) all Subject Shares then still subject to the Purchase
Right and (ii) the quotient of (A) the related Acceleration Purchase Price, divided by (B) the Fair Market Value of a Subject Share, determined as of three business days before the date of such acceleration, for a Purchase Price per
share equal to $0.01; provided, however, notwithstanding anything to the contrary in the foregoing, the Purchase Right shall not automatically be deemed exercised, as a result of, or in connection with, any of the transactions
contemplated by, relating to or resulting from that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of March 31, 2009 by and between Fidelity National Information Services, Inc., a Georgia Corporation,
Cars Holdings, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Fidelity National Information Services, Inc. and the Company, including without limitation, any acceleration of the vesting of the Subject Employee
Options in connection with, or as a result of, any of the transactions contemplated by the Merger Agreement or actions relating thereto. The Subject Shares shall be reduced by a number equal to one third of the number of Common Shares subject to Out
of the Money Options as of the date of an acceleration pursuant to this Section 3.2(c).” 
 (c) Effective as of the Effective Time,
each of Metavante and Investor hereby agrees that the Metavante Stock Purchase Right Agreement shall be deemed terminated and be of no further force or effect. 
 5.11. Entire Agreement. This Agreement constitutes the entire agreement and supersedes all prior agreements, understandings, representations and warranties, both written and oral, among the parties with respect
to the subject matter hereof and thereof. 
  

 -14- 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement by their authorized
representatives as of the date first above written. 
  

			
	FIDELITY NATIONAL INFORMATION SERVICES, INC.
		
	By:	 	 /s/ Lee A. Kennedy

	Name:	 	Lee A. Kennedy
	Title:	 	President and Chief Executive Officer

 [SIGNATURE PAGE TO STOCK PURCHASE RIGHT AGREEMENT] 

			
	WPM, L.P.

		
	By:	 	WPM GP, LLC, its general partner
		
	By:	 	 /s/ James Neary

	Name:	 	James Neary
	Title:	 	Managing Director

 [SIGNATURE PAGE TO STOCK PURCHASE RIGHT AGREEMENT] 

			
	METAVANTE TECHNOLOGIES, INC.
	 (Solely for the purpose of Sections 5.1, 5.8 and
 5.10)

		
	By:	 	 /s/ Donald W. Layden, Jr.

	Name:	 	Donald W. Layden, Jr.
	Title:	 	Senior Executive Vice President

 [SIGNATURE PAGE TO STOCK PURCHASE RIGHT AGREEMENT] 

 Exhibit A 
 Illustrative Example of the Computation of the Metavante Purchase Right pursuant to 
 Section 3.3. 
 For illustrative purposes only and using the assumptions below, the Metavante Purchase Right would be exercisable by the
Investor for 56 Common Shares (i.e., [1.35 * (1/3 * 200)]–(1/3 * 2,000/20)) at a per share purchase price of $0.01. Alternatively, the Metavante Purchase Right would be exercisable by the Investor for 90 Common Shares (i.e., 1.35
* (1/3 * 200)) for an aggregate purchase price of $666.66 (i.e., 1/3*$2,000). 
 Assumptions 
 (1) Closing Date: August 1, 2009. 
 (2) But for Section 5.10,
Metavante would have delivered a Quarterly Notice for the quarterly period ended March 31, 2009 on April 15, 2009, which Quarterly Notice indicates 50 shares of Metavante common stock were issued upon exercise of options to acquire
Metavante common stock during such quarter with an aggregate exercise price of $500. 
 (3) But for Section 5.10, Metavante would have delivered a
Quarterly Notice for the quarterly period ended June 30, 2009 on July 15, 2009, which Quarterly Notice indicates 50 shares of Metavante common stock were issued upon exercise of options to acquire Metavante common stock during such quarter
with an aggregate exercise price of $500. 
 (4) During the period beginning on July 1, 2009 through August 1, 2009, 100 shares of Metavante common
stock were issued upon exercise of options to acquire Metavante common stock during such period with an aggregate exercise price of $1,000. 
 (5) Fair
Market Value of a Share of Metavante common stock on the Closing Date: $20. 
 (6) Exchange Ratio: 1.35.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}]]